A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma
Clinical and Translational Oncology · 21.05.2024 · 26 (12) · 2966-2978
DOI: 10.1007/s12094-024-03515-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 21.05.2024. Verfasst von Yue Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Medical Award Foundation, Harbin Medical University Cancer Hospital Haiyan Scientific Research Fund.
Abstract (Originalsprache)
Purpose
Mitogen-activated protein kinase 12 (MAPK12), also known as p38γ, is a member of the p38 MAPK family and plays a crucial role in tumor occurrence and invasion. However, there is still uncertainty regarding MAPK12 involvement in diffuse large B-cell lymphoma (DLBCL).
Methods
Our study investigated the expression of MAPK12 mRNA in various types of cancer using bioinformatic analysis. Furthermore, we performed immunohistochemistry (IHC) to detect the expression of MAPK12 in patients with DLBCL and compared clinical indicators and survival rates.
Results
We found that the high expression rate of MAPK12 was 43.1% in DLBCL patients. Several clinical indicators, including IPI scores, Hans classifications, LDH levels, and Ki-67 expression were closely associated with MAPK12 expression. Survival analysis revealed that higher expression of MAPK12 was significantly correlated with shorter progression-free survival (PFS) and overall survival (OS) in DLBCL patients. In addition, both univariate and multivariate analyses revealed IPI score, MAPK12 expression, and rituximab use as the independent OS risk factors ( P < 0.05). To explore the functional role of MAPK12 in DLBCL, weighted gene co-expression network analysis (WGCNA) and gene ontology (GO) were used to confirm the involvement of MAPK12 in the regulation of type II interferon production, positive regulation of lymphocyte proliferation, and other related biological processes.
Conclusion
DLBCL patients have poor prognoses when MAPK12 levels are high, which is expected to be a therapeutic target and prognostic factor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. zs_1881@163.com.
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. zhangyue010@hotmail.com.
Förderung
- Beijing Medical Award Foundation
- Harbin Medical University Cancer Hospital Haiyan Scientific Research Fund
Zitieren
APA
Liu, Y., Zhang, H., Zhao, S., & Zhang, Y. (2024). A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma. Clinical and Translational Oncology, 26(12), 2966-2978. https://doi.org/10.1007/s12094-024-03515-3
Vancouver
Liu Y, Zhang H, Zhao S, Zhang Y. A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma. Clinical and Translational Oncology. 2024;26(12):2966-2978. doi:10.1007/s12094-024-03515-3
BibTeX
@article{Liu2024,
author = {Liu, Yue and Zhang, Han and Zhao, Shu and Zhang, Yue},
title = {A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma},
journal = {Clinical and Translational Oncology},
year = {2024},
volume = {26},
number = {12},
pages = {2966--2978},
doi = {10.1007/s12094-024-03515-3}
}
EUVIMED